Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Alliancebernstein L.P. lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 751.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 199,259 shares of the company’s stock after acquiring an additional 175,859 shares during the quarter. Alliancebernstein L.P. owned 0.85% of UroGen Pharma worth $2,122,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in URGN. KLP Kapitalforvaltning AS purchased a new stake in UroGen Pharma in the fourth quarter worth approximately $59,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in UroGen Pharma during the fourth quarter valued at $126,000. SG Americas Securities LLC lifted its holdings in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after acquiring an additional 6,207 shares during the period. Finally, FMR LLC boosted its position in UroGen Pharma by 575.1% in the third quarter. FMR LLC now owns 23,090 shares of the company’s stock worth $293,000 after purchasing an additional 19,670 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Stock Down 3.3 %

Shares of URGN stock opened at $10.39 on Thursday. The company has a market capitalization of $478.92 million, a price-to-earnings ratio of -3.30 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company’s fifty day moving average price is $10.52 and its 200-day moving average price is $11.23. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Sell-side analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Scotiabank started coverage on shares of UroGen Pharma in a research note on Wednesday. They issued a “sector outperform” rating and a $23.00 price objective on the stock. HC Wainwright decreased their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. Finally, LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, UroGen Pharma has a consensus rating of “Buy” and an average price target of $35.67.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.